Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS Iowa Emrelis Prior Authorization | OpenPayer
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - IowaPolicy 05.06.02

    Emrelis (telisotuzumab vedotin-tllv) Coverage for Non-Small Cell Lung Cancer

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Iowa Policy 05.06.02 alerts

    Get alerted when Policy 05.06.02 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity coverage for Emrelis in adult members with specified locally advanced, recurrent, or metastatic non-squamous non-small cell lung cancer. Coverage requires the documented clinical, biomarker, prior-treatment, and continuation criteria described in the policy.

    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyEmrelis (telisotuzumab vedotin-tllv) Coverage for Non-Small Cell Lung Cancer
    Policy CodePolicy 05.06.02
    Change TypeNo material clinical or coverage change
    Effective DateSeptember 30, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit the member's c-Met protein expression status and EGFR status to initiate prior authorization review.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥50%Required high c-Met expression
    12 monthsInitial authorization duration
    12 monthsContinuation authorization duration
    1.9 mg/kg

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    FDA-recommended dosing limit
    8 vialsStandard quantity limit
    J9326Current billing code

    Policy Background

    Emrelis (telisotuzumab vedotin-tllv) is covered under this policy for adult patients with locally advanced, recurrent, or metastatic non-squamous non-small cell lung cancer (NSCLC) when the policy’s clinical and biomarker requirements are met. Coverage includes patients with high c-Met protein overexpression demonstrated by an FDA-approved test and treatment with Emrelis as a single agent following prior systemic therapy.

    Coverage Determination

    Initial therapy - Non-small cell lung cancer

    Covered when all of the following are met:

    Initial therapy criteria

    • Disease status: Locally advanced, recurrent, or metastatic non-squamous NSCLC is present.
    • High c-Met expression: High c-Met protein overexpression is present.≥50% of tumor cells with strong (3+) staining
    • EGFR status: EGFR is wild-type.EGFR wild-type
    • Regimen: Emrelis is administered as a single agent for subsequent treatment.

    Continuation therapy - Non-small cell lung cancer

    Covered when all of the following are met:

    Continuation therapy

    • Qualifying indication: The indication remains one listed in the initial approval criteria.
    • No treatment-limiting toxicity or progression: There is no unacceptable toxicity and no disease progression while on the current regimen.

    Emrelis is considered not medically necessary for members who do not meet the criteria set forth in this policy.

    Initial Approval Criteria

    Initial approval - NSCLC

    Authorization of 12 months may be granted when all of the following are met:

    Initial approval for NSCLC

    • Disease status: The member has locally advanced, recurrent, or metastatic non-squamous NSCLC.
    • Biomarker status: The tumor has high c-Met protein overexpression, defined as at least 50% of tumor cells with strong (3+) staining.≥50% of tumor cells with strong (3+) staining
    • EGFR status: The tumor is EGFR wild-type.EGFR wild-type

    Continuation Authorization Criteria

    Continued treatment

    Authorization of 12 months may be granted for continued treatment when all of the following are met:

    • Qualifying indication: The member continues to meet an indication listed in the Criteria for Initial Approval section.
    • Treatment tolerance and response: There is no evidence of unacceptable toxicity or disease progression while on the current regimen.No unacceptable toxicity and no disease progression

    Dose and Quantity Limits

    Quantity Limits
    MedicationEmrelis (telisotuzumab vedotin-tllv) 20 mg/vial IV infusion and 100 mg/vial IV infusion
    Standard quantity limit8 vials per 28 days
    FDA-Recommended Dosing
    Dose1.9 mg/kg
    Route and administrationIntravenous infusion over 30 minutes every 2 weeks
    Treatment durationUntil disease progression or unacceptable toxicity
    Maximum dose190 mg for patients greater than or equal to 100 kg

    Coding and Clinical Parameters

    Current provider billing codeHCPCSCovered
    J9326Injection, telisotuzumab vedotin-tllv, 1 mg (effective 1/1/26)
    Cancelled provider billing codeHCPCS
    C9306Injection, telisotuzumab vedotin-tllv, 1 mg (cancelled 12/31/25)
    High c-Met Protein Overexpression
    BiomarkerHigh c-Met protein overexpression
    Required thresholdAt least 50% of tumor cells with strong (3+) staining
    Test requirementDetermined by an FDA-approved test
    Maximum Dose
    Patient weightGreater than or equal to 100 kg
    Maximum dose190 mg

    Authorization and Denial Considerations

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required. Coverage is available when all applicable approval criteria are met and the member has no exclusions to the prescribed therapy. Submit the required clinical documentation to initiate review.

    • Document the qualifying indication and treatment setting.
    • Confirm the member meets the applicable biomarker and clinical criteria.
    Documentation Required

    Required Biomarker Documentation

    Submit biomarker documentation with the prior authorization request for review.

    • c-Met protein expression status
    • EGFR status
    Policy Summary
    PayerBlue Cross Blue Shield - Iowa
    PolicyEmrelis (telisotuzumab vedotin-tllv) Coverage for Non-Small Cell Lung Cancer
    Policy CodePolicy 05.06.02
    Change TypeNo material clinical or coverage change
    Effective DateSeptember 30, 2026
    Last ReviewAug 1, 2026
    Next Review DateN/A
    Key ActionSubmit the member's c-Met protein expression status and EGFR status to initiate prior authorization review.
    SourceLink
    On This Page
    Policy BackgroundCoverage DeterminationInitial Approval CriteriaContinuation Authorization CriteriaDose and Quantity LimitsCoding and Clinical ParametersAuthorization and Denial Considerations
  1. Treatment context: Emrelis is being used as a single agent for subsequent treatment.
  2. Denial Risk

    Failure to Meet Coverage Criteria

    Emrelis (telisotuzumab vedotin-tllv) is considered not medically necessary when the member does not meet the policy criteria.

    Denial Risk

    Nonqualifying NSCLC or Biomarker Status

    Initial authorization may be denied when the disease or biomarker status does not qualify for coverage. For NSCLC, the policy requires subsequent treatment of locally advanced, recurrent, or metastatic non-squamous NSCLC with high c-Met protein overexpression and EGFR wild-type status, as a single agent.

    • High c-Met protein overexpression: ≥50% of tumor cells with strong (3+) staining
    • EGFR status must be wild-type
    Denial Risk

    Toxicity or Disease Progression

    Continuation authorization may be denied if there is evidence of unacceptable toxicity or disease progression while the member is receiving the current regimen.

    • For reauthorization, document that the member is continuing treatment for an indication listed in the Initial Approval criteria.
    • Confirm there is no evidence of unacceptable toxicity or disease progression.